M&A Deal Summary |
|
---|---|
Date | 2024-08-07 |
Target | G1 Therapeutics |
Sector | Life Science |
Buyer(s) | Pharmacosmos |
Deal Type | Add-on Acquisition |
Deal Value | 405M USD |
Advisor(s) | Centerview Partners (Financial) Ropes & Gray Mintz Levin Cohn Ferris Glovsky and Popeo PC (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Pharmacosmos is a specialized company focused on carbohydrate chemistry and a developer of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia. Pharmacosmos is based in Holbaek, Denmark.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 2 of 2 |
Type (Add-on Acquisition) | 2 of 2 |
State (North Carolina) | 1 of 1 |
Country (United States) | 2 of 2 |
Year (2024) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-11-11 |
AbFero Pharmaceuticals
Boston, Massachusetts, United States AbFero Pharmaceuticals is a clinical stage pharmaceutical company dedicated to treating diseases of iron overload. The company therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with diseases of aging such as age-related macular degeneration (AMD) and Parkinson's disease. AbFero Pharmaceuticals is based in Boston, Massachusetts. |
Buy | $225M |